FRX vs. SVA, MDNA, ONC, ACB, KSI, VHI, DR, OGI, QIPT, and CPH
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Sernova (SVA), Medicenna Therapeutics (MDNA), Oncolytics Biotech (ONC), Aurora Cannabis (ACB), kneat.com (KSI), Vitalhub (VHI), Medical Facilities (DR), Organigram (OGI), Quipt Home Medical (QIPT), and Cipher Pharmaceuticals (CPH). These companies are all part of the "medical" sector.
Fennec Pharmaceuticals (TSE:FRX) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
Sernova has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -75.50%. Sernova's return on equity of -183.58% beat Fennec Pharmaceuticals' return on equity.
Sernova has a consensus price target of C$1.50, indicating a potential upside of 244.83%. Given Sernova's higher probable upside, analysts clearly believe Sernova is more favorable than Fennec Pharmaceuticals.
In the previous week, Fennec Pharmaceuticals had 3 more articles in the media than Sernova. MarketBeat recorded 3 mentions for Fennec Pharmaceuticals and 0 mentions for Sernova. Fennec Pharmaceuticals' average media sentiment score of 1.05 beat Sernova's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
55.2% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Sernova shares are held by institutional investors. 17.0% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of Sernova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Fennec Pharmaceuticals received 95 more outperform votes than Sernova when rated by MarketBeat users. However, 88.89% of users gave Sernova an outperform vote while only 69.59% of users gave Fennec Pharmaceuticals an outperform vote.
Fennec Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Sernova has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.
Fennec Pharmaceuticals has higher revenue and earnings than Sernova. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.
Summary
Fennec Pharmaceuticals beats Sernova on 8 of the 15 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
